Obtaining the drug certificate is in continuation of Sinovac’s strategy to explore opportunities to export its vaccines manufactured in mainland China to targeted areas and countries worldwide.
Sinovac Biotech (Hong Kong) has submitted the application for Anflu in November 2009.
Sinovac chairman, president and CEO Weidong Yin said that they are advancing international sales strategy by obtaining regulatory approvals in targeted areas and countries that will enable them generate sales by exporting commercialised vaccines.
"We have successfully registered Anflu in Hong Kong and are actively evaluating marketing and distribution opportunities in this market," Yin said.